Merck: Keytruda partially convincing in urothelial cancer
In the first interim analysis, after a median follow-up of 22.3 months, Keytruda demonstrated a 'statistically and clinically significant' improvement in disease-free survival (DFS), one of the study's two primary endpoints.
In fact, the treatment reduced the risk of disease recurrence or death by 31% compared with observation of patients after surgery.
However, the other primary endpoint - overall survival (OS) - did not reach statistical significance at the time of this interim analysis.
Thus, after a median follow-up of 36.9 months, median OS was 50.9 months for Keytruda versus 55.8 months for the post-surgery observation.
Overall survival will therefore continue to be monitored as the data mature, reports the laboratory.
The results of this pivotal study support Keytruda as a potential new adjuvant option for these patients, and demonstrate its growing role in early-stage bladder cancer," said Dr. Marjorie Green, Senior Vice President and Head of Oncology and Global Clinical Development at Merck Research Laboratories.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction